Human Reproduction, Vol. 18, No. 1, 152-166,
January 2003
© 2003 European Society of Human Reproduction and Embryology
Expression of erythropoietin and erythropoietin receptor in peritoneal endometriosis
1 Department of Obstetrics & Gynecology, Tohoku University School of Medicine, 11, Seiryo-machi, Aoba-ku, Sendai, 9808574, Japan and 2 Department of Gynecology, Polyclinique de lHotel-Dieu, 13, boulevard Charles-De-Gaulle, 63003 Clermont-Ferrand Cedex 1, France 3 Present address: Department of Gynecology, Polyclinique de lHotel-Dieu, 13, boulevard Charles-De-Gaulle, 63003 Clermont-Ferrand Cedex 1, France 4 To whom correspondence should be addressed at: Department of Gynecology, Polyclinique de lHôtel-Dieu, 13, boulevard Charles-De-Gaulle, 63003 Clermont-Ferrand Cedex 1, France. e-mail: SachikoMA{at}aol.com
| Abstract |
|---|
|
|
|---|
BACKGROUND: Recent studies have indicated new physiological roles for erythropoietin (Epo) unrelated to erythropoiesis. We previously demonstrated that the Epo concentrations in peritoneal fluid from patients with stage I endometriosis were significantly higher than those with stages II, III and IV of the disease. Therefore, we hypothesized that Epo may play a role in the pathogenesis of endometriosis, particularly during the early stages of the disease. METHOD: We investigated the localization of Epo and the Epo receptor (Epo-R) in peritoneal endometriosis and eutopic endometrium, using immunohistochemistry. RESULTS: We detected Epo and Epo-R localized within glandular epithelial cells in both peritoneal endometriosis and eutopic endometrium. There was no significant difference in Epo expression between red and black peritoneal lesions, whereas Epo-R expression was significantly lower in black peritoneal lesions when compared to red lesions. Epo and Epo-R expression levels within red peritoneal lesions were comparable to those of eutopic endometrium from patients with endometriosis. CONCLUSION: The present findings suggest that Epo may play a role in the pathophysiology of endometriosis.
Key words: black endometriotic lesions/erythropoietin/erythropoietin-receptor/red endometriotic lesions
| Introduction |
|---|
|
|
|---|
Erythropoietin (Epo) has a molecular weight of
30 kDa (Tilbrook and Klinken, 1999In the present study we investigated the localization of Epo and Epo-R expression within peritoneal endometriosis, using immunohistochemistry. In addition, we compared the expression levels of Epo and Epo-R in red and black peritoneal lesions, in order to evaluate the pathophysiological significance of Epo in peritoneal endometriosis.
| Materials and methods |
|---|
|
|
|---|
Experimental subjects
Patients undergoing laparoscopic surgery for infertility or investigation of pelvic pain, or a pelvic mass, were recruited for the study. None of the patients received hormonal treatments, such as GnRH agonist or sex steroids, during a minimum 6 month period preceding surgery. All patients had regular menstrual cycles, confirmed by their menstrual history and measurement of their serum 17ß-estradiol and progesterone levels. During laparoscopic surgery, paired samples of peritoneal endometriotic lesions (25 mm in size, n = 44) and eutopic endometrium were obtained from a total of 23 patients (2338 years of age) at Tohoku University Hospital, Sendai, Japan and Polyclinique de lHôtel-Dieu, Clermont-Ferrand, France. Peritoneal endometriotic lesions were further categorized as red, black or white lesions as proposed in the latest revision of the American Society for Reproductive Medicine classification (American Society for Reproductive Medicine, 1997). Finally, 21 samples were categorized as red lesions (including red, red-pink and clear lesions, 10 in the proliferative phase and 11 in the secretory phase) and the remaining 23 samples were of black lesions (including black and blue lesions, 10 in the proliferative phase and 13 in the secretory phase). Eutopic endometrial tissues were obtained from 23 patients (10 in the proliferative phase and 13 in the secretory phase as determined using established criteria) (Noyes et al., 1950
Immununohistochemical staining
Immunohistochemical staining was performed on paraffin sections using a goat polyclonal antibody against human erythropoietin (Santa Cruz Biotechnology, Santa Cruz, CA, USA), or a rabbit polyclonal antibody against the human erythropoietin receptor (Santa Cruz Biotechnology). Immunohistochemistry for Epo and Epo-R was performed using a commercial streptavidin-biotin system (Histofine kit; Nichirei, Tokyo, Japan) and has been previously described in detail (Yokomizo et al., 2002
). The primary antibody, either anti-human Epo or anti-human Epo-R, was diluted 1:100 in PBS with 3% bovine serum albumin. Specific immunolocalization of Epo and Epo-R has been reported previously in human placenta and fetal kidney; therefore, these tissues were chosen as positive controls (Conrad et al., 1996
; Juul et al., 1998a
; Juul et al., 1998b
; Fairchild Benyo and Conrad, 1999
; Yokomizo et al., 2002
). Negative controls were performed by replacing the primary antibody with normal goat IgG (for Epo) or rabbit IgG (for Epo-R) diluted at the same concentration as the primary antibody.
Quantitation of Epo and Epo-R immunostained cells
To quantify immunopositivity, positively stained cells were counted as previously reported (Yokomizo et al., 2002
). For each section, the number of positive cells was counted, regardless of the staining intensity. In all samples of eutopic endometrium, 10 non-overlapped fields were analysed. In peritoneal endometriosis, because of the tissue heterogeneity, we analysed all glandular and stromal cells within each sample. The number of areas analysed in peritoneal endometriosis varied from five to 13 areas per sample. The percentage of positive cells for Epo or Epo-R was calculated for each sample.
Statistical analysis
Statistical analysis was performed with the Stat View 4.5 program (Abacus concepts, Inc., Berkeley, CA, USA). The Kruskal-Wallis test or MannWhitney U-test was applied to compare results from different groups. Statistical significance was defined as P < 0.05.
| Results |
|---|
|
|
|---|
Erythropoietin expression
The results are shown in Figure 1 and Table I. Homogeneous cytoplasmic immunoreactivity to erythropoietin was detected in glandular epithelial cells, while stromal cells stained heterogeneously for eutopic endometrium and peritoneal endometriosis samples at each stage of the menstrual cycle. The percentage of positive glandular epithelial cells was significantly increased in secretory eutopic endometrium when compared to proliferative eutopic endometrium (P < 0.01). No significant change was detected in peritoneal endometriotic tissues between each phase of the menstrual cycle. During the proliferative phase, there was no significant difference in the percentage of positive glandular epithelial cells among eutopic endometrium, black or red peritoneal lesions. During the secretory phase, the percentage of positive glandular epithelial cells found in red lesions was similar to that of eutopic endometrium, whereas that in black lesions was significantly lower in number than in eutopic endometrium (P < 0.02). However, there was no significant difference in the percentage of positive glandular epithelial cells between red and black peritoneal lesions. The percentage of positive stromal cells was <1% in both eutopic endometrium and peritoneal endometriosis at each phase of the menstrual cycle.
|
|
Erythropoietin receptor expression
The results are shown in Figure 1 and Table I. Cytoplasmic immunoreactivity to Epo-R was observed to be homogenous in glandular epithelial cells and heterogeneous in stromal cells within eutopic endometrium and peritoneal endometriosis tissue at each stage of the menstrual cycle. No significant cyclical change in Epo-R immunoreactivity was detected in glandular epithelial or stromal cells either in eutopic endometrium or peritoneal endometriosis samples. Black lesions possessed the lowest percentage of positive glandular epithelial cells when compared to eutopic endometrium tissue (proliferative phase; P < 0.02, secretory phase; P < 0.001) or red lesions (proliferative phase; P < 0.04, secretory phase; P < 0.004). There was no significant difference in the percentage of positive glandular epithelial cells between eutopic endometrium and red peritoneal lesions. The percentage of positive stromal cells was <1% in both eutopic endometrium and peritoneal endometriosis tissue at each phase of the menstrual cycle.
| Discussion |
|---|
|
|
|---|
In the present study we detected Epo and Epo-R localization in glandular epithelial cells in peritoneal endometriosis as well as in eutopic endometrium. The present study and our previous studies (Matsuzaki et al., 2001a
The functional role of Epo and Epo-R in endometriosis remains to be determined. A recent study demonstrated high expression levels of Epo and Epo-R in human solid tumours and in vitro stimulation of cell proliferation of breast cancer cells by Epo (Acs et al., 2001
). Inhibition of Epo signalling induces tumour regression of xenografts of ovarian and uterine cancers in nude mice (Yasuda et al., 2001
). Our recent study suggests that Epo may be involved in cyclic proliferation and differentiation of endometrial epithelial cells, acting in an autocrine mechanism (Yokomizo et al., 2002
). The present study showed prominent expression of Epo in glandular epithelial cells in peritoneal endometriosis and no significant difference between red and black peritoneal lesions. However, we detected that Epo-R immunoreactivity was significantly lower in black peritoneal lesions when compared to red ones. Black peritoneal lesions have lower cell-proliferating activity compared with red ones (Nisolle and Donnez, 1997
; Matsuzaki et al., 2001b
). A recent study demonstrated that downregulation of Epo-R by interferon (IFN)-
led to a reduced effect of Epo on erythroid cell proliferation and differentiation (Taniguchi et al., 1997
). Studies demonstrated that IFN-
inhibited the proliferation of endometrial and endometriotic epithelial cells (Tabibzadeh et al., 1988
; Klein et al., 1993
). Furthermore, we previously reported increased expression of cell cycle inhibitor p27Kip1 in black lesions compared with red lesions, suggesting that expression of p27Kip1 is involved in progression of peritoneal endometriosis ( Matsuzaki et al., 2001b
). p27Kip1 has a role in mediating IFN-
-induced terminal growth arrest (Mandal et al., 1998
). The present findings suggest that Epo may play a role in the pathophysiology of endometriosis. We hypothesize that local production of Epo in endometrial, endometriotic and activated macrophages in PF may be involved in the development and growth of peritoneal endometriosis and that the down-regulation of Epo-R expression may possibly lead to a reduced effect of Epo on cell proliferation in black peritoneal lesions. However, comparisons between red and black lesions by a morphometric approach have some unavoidable limitations. The different morphological appearance of red and black lesions makes it easy to identify the laparoscopic appearance from each section (Nisolle et al., 1993
; Nisolle and Donnez, 1997
). Further studies are required to clarify roles of Epo and Epo-R in the pathogenesis of peritoneal endometriosis.
| Acknowledgements |
|---|
We are grateful to Ms Keiko Abe and Mr Satoshi Okamoto for their expert technical assistance.
| References |
|---|
|
|
|---|
Acs, G., Acs, P., Beckwith, S.M., Pitts, R.L., Clements, E., Wong, K. and Verna, A. (2001) Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res., 61, 35613565.
American Society for Reproductive Medicine (1997) Revised American Society for Reproductive Medicine classification of endometriosis: 1996. Fertil. Steril., 67, 817821.[CrossRef][Web of Science][Medline]
Ribatti, D., Presta, M., Vacca, A., Ria, R., Giuliani, R., DellEra, P., Nico, B., Roncali, L. and Dammacco, F. (1994) Erythropoietin receptor mRNA expression in human endothelial cells. Proc. Natl Acad. Sci. USA, 91, 39743978.
Bikfalvi, A. and Han, Z.C. (1994) Angiogenic factors are hematopoietic growth factors and vice versa. Leukemia, 8, 523529.[Web of Science][Medline]
Calhaz-Jorge, C., Costa, A.P., Barata, M., Santos, M.C., Melo, A. and Palma-Carlos, M.L. (2000) Tumour necrosis factor alpha concentrations in the peritoneal fluid of infertile women with minimal or mild endometriosis are lower in patients with red lesions only than in patients without red lesions. Hum. Reprod., 15, 12561260.
Chandra, M., Clemons, G., Sahdev, I., McVicar, M. and Bluestone, P. (1993) Intraperitoneal production of erythropoietin with continuous ambulatory peritoneal dialysis. Pediatr. Nephrol., 7, 281283.[CrossRef][Web of Science][Medline]
Conrad, K.P., Benyo, D.F., Westerhausen-Larsen, A. and Miles, T.M. (1996) Expression of erythropoietin by the human placenta. F.A.S.E.B. J., 10, 760766.[Abstract]
Donnez, J., Smoes, P., Gillerot, S., Casanas-Roux, F. and Nisolle, M. (1998) Vascular endothelial growth factor (VEGF) in endometriosis. Hum. Reprod., 13, 16861690.
Fairchild Benyo, D. and Conrad, K.P. (1999) Expression of the erythropoietin receptor by trophoblast cells in the human placenta. Biol. Reprod., 60, 861870.
Halme, J., White, C., Kauma, S., Estes, J. and Haskill, S. (1988) Peritoneal macrophages from patients with endometriosis release growth factor activity in vitro. J. Clin. Endocrinol. Metab., 66, 10441049.
Healy, D.L., Rogers, P.A., Hii, L. and Wingfield, M. (1998) Angiogenesis: a new theory for endometriosis. Hum. Reprod. Update, 4, 736740.
Jelkmann, W. (1992) Erythropoietin: Structure, control of production, and function. Physiol. Rev., 72, 449489.
Juul, S.E., Anderson, D.K., Li, Y. and Christensen, R.D. (1998a) Erythropoietin and erythropoietin receptor in the developing human central nervous system. Pediatr. Res., 43, 4049.[Web of Science][Medline]
Juul, S.E., Yachnis, A.T. and Christensen, R.D. (1998b) Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus. Early Hum. Dev., 52, 235249.[CrossRef][Web of Science][Medline]
Klein, N.A., Pergola, G.M., Rao-Tekmal, R., Dey, T.D. and Schenken, R.S. (1993) Enhanced expression of resident leukocyte interferon gamma mRNA in endometriosis. Am. J. Reprod. Immunol., 30, 7481.
Koninckx, P.R., Kennedy, S.H. and Barlow, D.H. (1998) Endometriotic disease: the role of peritoneal fluid. Hum. Reprod. Update, 4, 741751.
Krantz, S.B. (1991) Erythropoietin. Blood, 77, 419434.
Mandal, M., Bandyopadhyay, D., Goepfert, T.M. and Kumar, R. (1998) Interferon-induces expression of cyclin-dependent kinase-inhibitors p21WAF1 and p27Kip1 that prevent activation of cyclin-dependent kinase by CDK-activating kinase (CAK). Oncogene, 16, 217225.[CrossRef][Web of Science][Medline]
Matsuzaki, S., Murakami, T., Uehara, S., Yokomizo, R., Noda, T., Kimura, Y. and Okamura, K. (2001a) Erythropoietin concentrations are elevated in the peritoneal fluid of women with endometriosis. Hum. Reprod., 16, 945948.
Matsuzaki, S., Canis, M., Murakami T., Dechelotte, P., Bruhat, M.A. and Okamura, K. (2001b) Expression of the cyclin-dependent kinase inhibitor p27Kip1 in eutopic endometrium and peritoneal endometriosis. Fertil. Steril., 75, 956960.[CrossRef][Web of Science][Medline]
Masuda, S., Okano, M., Yamagishi, K., Nagao, M., Ueda, M. and Sasaki, R. (1994) A novel site of erythropoietin production. J. Biol. Chem., 269, 1948819493.
Masuda, S, Nagao, M. and Sasaki, R. (1999) Erythropoietic, neurotrophic, and angiogenic functions of erythropoietin and regulation of erythropoietin production. Int. J. Hematol., 70, 16.[Web of Science][Medline]
Nisolle, M., Casanas-Roux, F., Anaf, V., Mine, J.M. and Donnez, J. (1993) Morphometric study of the stromal vascularization in peritoneal endometriosis. Fertil. Steril., 59, 681684.[Web of Science][Medline]
Nisolle, M. and Donnez, J. (1997) Peritoneal endometriosis, ovarian endometriosis, and adenomyotic nodules of the rectovaginal septum are three different entities. Fertil. Steril., 68, 585596.[CrossRef][Web of Science][Medline]
Nisolle, M., Casanas-Roux, F. and Donnez, J. (1997) Immunohistochemical analysis of proliferative activity and steroid receptor expression in peritoneal and ovarian endometriosis. Fertil. Steril., 68, 912919.[CrossRef][Web of Science][Medline]
Noyes, R.W., Hertig, A.T. and Rock, J. (1950) Dating the endometrial biopsy. Fertil. Steril., 1, 35.
Tabibzadeh, S.S., Satyaswaroop, P.G. and Rao, P.N. (1988) Antiproliferative effect of interferon-gamma in human endometrial epithelial cells in vitro: potential local growth modulatory role in endometrium. J. Clin. Endocrinol. Metab., 67, 131138.
Taniguchi, S., Dai, C.H., Price, J.O. and Krantz, S.B. (1997) Interferon gamma downregulates stem cell factor and erythropoietin receptors but not insulin-like growth factor-I receptors in human erythroid colony-forming cells. Blood, 90, 22442252.
Tilbrook, P.A. and Klinken, S.P. (1999) Erythropoietin and erythropoietin receptor. Growth Factors, 17, 2535.[Web of Science][Medline]
Yasuda, Y., Musha, T., Tanaka, H., Fujita, Y., Fujita, H., Utsumi, H., Matsuo, T., Masuda, S., Nagao, M., Sasaki, R. et al. (2001) Inhibition of erythropoietin signalling destroys xenografts of ovarian and uterine cancers in nude mice. Br. J. Cancer, 84, 836843.[CrossRef][Web of Science][Medline]
Yasuda, Y., Masuda, S., Chikuma, M., Inoue, K., Nagao, M. and Sasaki, R. (1998) Estrogen-dependent production of erythropoietin in uterus and its implication in uterine angiogenesis. J. Biol. Chem., 273, 2538125387.
Yokomizo, R., Matsuzaki, S., Uehara, S., Murakami, T., Yaegashi, N. and Okamura, K. (2002) Erythropoietin and erythropoietin receptor expression in human endometrium throughout the menstrual cycle. Mol. Hum. Reprod., 8, 441446.
Submitted on April 18, 2002; resubmitted on June 27, 2002; accepted on September 5, 2002
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
L. Bujan, M. Sergerie, N. Moinard, S. Martinet, L. Porte, P. Massip, C. Pasquier, and M. Daudin Decreased Semen Volume and Spermatozoa Motility in HIV-1-Infected Patients Under Antiretroviral Treatment J Androl, May 1, 2007; 28(3): 444 - 452. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

